BR0016257A - Método para testar um efeito de uma substância como um agente terapêutico ou preventivo para a hiperlipidemia. polinucleotìdeo, dna, anticorpo que reconhece especificamente um polipetìdeo, kit para testar um agente terapêutico ou preventivo para a hiperlipidemia, uso de um polinucleotìdeo, uso de um polipetìdeo, uso de um anticorpo que reconhece especificamente um polipeptìdeo, dna ou rna e agente terapêutico para a hiperlipidemia. - Google Patents

Método para testar um efeito de uma substância como um agente terapêutico ou preventivo para a hiperlipidemia. polinucleotìdeo, dna, anticorpo que reconhece especificamente um polipetìdeo, kit para testar um agente terapêutico ou preventivo para a hiperlipidemia, uso de um polinucleotìdeo, uso de um polipetìdeo, uso de um anticorpo que reconhece especificamente um polipeptìdeo, dna ou rna e agente terapêutico para a hiperlipidemia.

Info

Publication number
BR0016257A
BR0016257A BR0016257-4A BR0016257A BR0016257A BR 0016257 A BR0016257 A BR 0016257A BR 0016257 A BR0016257 A BR 0016257A BR 0016257 A BR0016257 A BR 0016257A
Authority
BR
Brazil
Prior art keywords
therapeutic
hyperlipidemia
polypeptide
antibody
dna
Prior art date
Application number
BR0016257-4A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0016257A publication Critical patent/BR0016257A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODO PARA TESTAR UM EFEITO DE UMA SUBSTâNCIA COMO UM AGENTE TERAPêUTICO OU PREVENTIVO PARA A HIPERLIPIDEMIA. POLINUCLEOTìDEO, DNA, ANTICORPO QUE RECONHECE ESPECIFICAMENTE UM POLIPEPTìDEO, KIT PARA TESTAR UM AGENTE TERAPêUTICO OU PREVENTIVO PARA A HIPERLIPIDEMIA, USO DE UM POLINUCLEOTìDEO, USO DE UM POLIPEPTìDEO, USO DE UM ANTICORPO QUE RECONHECE ESPECIFICAMENTE UM POLIPEPTìDEO, DNA OU RNA E AGENTE TERAPEUTICO PARA A HIPERLIPIDEMIA". A presente invenção fornece um novo método para testar um agente terapêutico ou preventivo para a hiperlipidemia e uma sonda de ácido nucléico, um iniciador e um anticorpo que são usados no método. Especificamente pode ser fornecido um método para testar o efeito de uma substância de teste como um agente terapêutico ou preventivo para a hiperlipidemia pela expressão de um gene apresentado na SEQ ID No. 1 e na SEQ ID No. 2 da Listagem de Seq³ência que participa na regulagem da concentração de gordura neutra no sangue de um mamífero e uma sonda de ácido nucléico, iniciador ou anticorpo usando para o método. De acordo com método da presente invenção, possível a pesquisa de uma substância candidata para um agente terapêutico ou preventivo para a hiperlipidemia.
BR0016257-4A 1999-12-09 2000-12-08 Método para testar um efeito de uma substância como um agente terapêutico ou preventivo para a hiperlipidemia. polinucleotìdeo, dna, anticorpo que reconhece especificamente um polipetìdeo, kit para testar um agente terapêutico ou preventivo para a hiperlipidemia, uso de um polinucleotìdeo, uso de um polipetìdeo, uso de um anticorpo que reconhece especificamente um polipeptìdeo, dna ou rna e agente terapêutico para a hiperlipidemia. BR0016257A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34997699 1999-12-09
PCT/JP2000/008722 WO2001042499A1 (en) 1999-12-09 2000-12-08 Method of testing remedy or preventive for hyperlipemia

Publications (1)

Publication Number Publication Date
BR0016257A true BR0016257A (pt) 2002-08-20

Family

ID=18407394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016257-4A BR0016257A (pt) 1999-12-09 2000-12-08 Método para testar um efeito de uma substância como um agente terapêutico ou preventivo para a hiperlipidemia. polinucleotìdeo, dna, anticorpo que reconhece especificamente um polipetìdeo, kit para testar um agente terapêutico ou preventivo para a hiperlipidemia, uso de um polinucleotìdeo, uso de um polipetìdeo, uso de um anticorpo que reconhece especificamente um polipeptìdeo, dna ou rna e agente terapêutico para a hiperlipidemia.

Country Status (17)

Country Link
US (3) US20030017488A1 (pt)
EP (1) EP1239050A4 (pt)
KR (1) KR20020062652A (pt)
CN (1) CN1433482A (pt)
AU (1) AU768034B2 (pt)
BR (1) BR0016257A (pt)
CA (1) CA2390676A1 (pt)
CZ (1) CZ20021853A3 (pt)
HK (1) HK1045541A1 (pt)
HU (1) HUP0203408A3 (pt)
IL (1) IL149849A0 (pt)
MX (1) MXPA02005758A (pt)
NO (1) NO20022711L (pt)
PL (1) PL355666A1 (pt)
RU (1) RU2002115295A (pt)
WO (1) WO2001042499A1 (pt)
ZA (1) ZA200204432B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036808A2 (en) * 2000-11-03 2002-05-10 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
EP1403367A4 (en) * 2001-06-08 2005-08-17 Sankyo Co A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA
WO2003028445A1 (en) * 2001-08-31 2003-04-10 Otsuka Pharmaceutical Co., Ltd. Tsa2306 knockout non-human animal
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8143600B2 (en) * 2008-02-18 2012-03-27 Visiongate, Inc. 3D imaging of live cells with ultraviolet radiation
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
HUE052243T2 (hu) 2013-12-24 2021-04-28 Ionis Pharmaceuticals Inc Az angiopoietin-szerû 3 expressziójának modulációja
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
PE20201287A1 (es) 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
CN109806632A (zh) * 2019-03-01 2019-05-28 中国科学院武汉物理与数学研究所 一种全血过滤装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
AU1181900A (en) * 1998-11-17 2000-06-05 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
JP3695642B2 (ja) * 1998-12-01 2005-09-14 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
IL143031A0 (en) * 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2000325087A (ja) * 1999-05-21 2000-11-28 Otsuka Pharmaceut Co Ltd Ｔｓａ２３０６遺伝子
AU6605900A (en) * 1999-07-16 2001-02-05 Hyseq, Inc. Novel angiopoietin materials and methods
ATE368110T1 (de) * 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten

Also Published As

Publication number Publication date
CZ20021853A3 (cs) 2002-11-13
EP1239050A4 (en) 2004-07-21
KR20020062652A (ko) 2002-07-26
CN1433482A (zh) 2003-07-30
ZA200204432B (en) 2003-09-29
US20030207251A1 (en) 2003-11-06
AU768034B2 (en) 2003-11-27
HUP0203408A2 (hu) 2003-01-28
AU1887001A (en) 2001-06-18
NO20022711D0 (no) 2002-06-07
MXPA02005758A (es) 2002-09-18
NO20022711L (no) 2002-08-08
US20030211533A1 (en) 2003-11-13
HUP0203408A3 (en) 2005-01-28
US20030017488A1 (en) 2003-01-23
HK1045541A1 (en) 2002-11-29
EP1239050A1 (en) 2002-09-11
RU2002115295A (ru) 2004-01-10
CA2390676A1 (en) 2001-06-14
PL355666A1 (en) 2004-05-04
IL149849A0 (en) 2002-11-10
WO2001042499A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
Heuer et al. Mapping Features of HIV-1 Integrase Near Selected Sites on Viral and Target DNA Molecules in an Active Enzyme− DNA Complex by Photo-Cross-Linking
Camerini-Otero et al. Histone H3 disulfide dimers and nucleosome structure.
Johnston et al. Nucleotide sequence of the luxB gene of Vibrio harveyi and the complete amino acid sequence of the beta subunit of bacterial luciferase.
Khan et al. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus
HUP9900459A2 (hu) Eljárások és készítmények ligandumpár kötődésének nem fluoreszcens jelölőanyag alkalmazásával történő kimutatására
ES2240979T3 (es) Enzima para la escision de la region de anclaje de las proteinas superficiales de bacterias gram positivas.
ES539560A0 (es) Perfeccionamientos en las disposiciones para la deteccion desecuencias determinadas de nucleotidos, procedimiento de deteccion y de caracterizacion de una secuencia o de un fragmento de acido nucleico determinado y sonda clonad
Levilliers et al. Monoclonal and polyclonal antibodies detect a new type of post-translational modification of axonemal tubulin
Langsetmo et al. Escherichia coli thioredoxin folds into two compact forms of different stability to urea denaturation
Colland et al. The interaction between σS, the stationary phase σ factor, and the core enzyme of Escherichia coli RNA polymerase
Liang et al. Reversible denaturation of the gene V protein of bacteriophage f1
BR9711238A (pt) Processo para testar homocisteìna em uma amostra, para testar um análito degradável para homocisteìna, para testar metionina, cisteìna ou o-acetil-l-serina em uma amostra, kit para determinação diasgnóstica in vitro de um nìvel de homocisteìna em uma amostra, fragmento de polinucleotìdeo, molécula de ácido nucleico recombinante, célula hospedeira eucariótica ou procariìotica, polipeptìdeo de dessulfurase de homocistéina recombinante de protozoários, ou derivado funcionalmente ativo do mesmo, anticorpo, dessulfurase de homocisteìna recombinante de protozoários, ou derivado funcionalmente ativo da mesma, uso de um polipeptìdeo recombinante ou derivado funcionalmente ativo do mesmo, e, composição farmacêutica.
YUBISUI et al. Amino acid sequence of NADH-cytochrome b 5 reductase of human erythrocytes
Simons et al. Sulfur mustard-induced epigenetic modifications over time− a pilot study
Maltseva et al. Replication protein A as a modulator of the poly (ADP-ribose) polymerase 1 activity
DE59510255D1 (de) Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems
NO20022711L (no) Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi
Ang et al. Mitochondrial thiol oxidase Erv1: both shuttle cysteine residues are required for its function with distinct roles
Żabka et al. Sgt1 has co-chaperone properties and is up-regulated by heat shock
Tardos et al. SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais
MacFerrin et al. [7] Overproduction of proteins using expression-cassette polymerase chain reaction
Laptenko et al. Biochemical assays of Gre factors of Thermus thermophilus
DE69032329D1 (de) Für c.difficile spezifische oligonukleotide
KR960703434A (ko) D4 도파민 수용체의 합성 유전자(a synthetic gene for d4 dopamine receptors)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.